A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

NCT06585488 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

514

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Solid Tumors
Advanced Non-squamous Non-small-cell Lung Cancer
Advanced Colorectal Cancer
Advanced Pancreatic Ductal Adenocarcinoma
Advanced Gastric Cancer
Advanced Gastroesophageal Junction Cancer
Advanced Esophageal Adenocarcinoma

Interventions

DRUG: BGB-53038
DRUG: Tislelizumab
DRUG: Cetuximab

Sponsor

BeiGene